2. Search Result
Search Result
Results for "

calcium flux

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-120620
    BMS-195270

    		Others Others
    BMS-195270 is a small molecule that inhibits Carbachol (HY-B1208)-evoked tonicity of isolated rat bladder strips. BMS-195270 inhibits calcium flux .
    BMS-195270
  • HY-114865
    BMS-192364

    		RGS Protein Calcium Channel Neurological Disease
    BMS-192364 is targeting the Gα-RGS interaction to produce an inactive Gα-RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux .
    BMS-192364
  • HY-148129
    TRPC6-IN-3

    		TRP Channel Cardiovascular Disease
    TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system .
    TRPC6-IN-3
  • HY-P99190
    Eldelumab

    BMS-936557; MDX-1100

    		 CXCR Inflammation/Immunology
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
    Eldelumab
  • HY-146401
    CXCR4 antagonist 6

    		CXCR Cancer
    CXCR4 antagonist 6 (compound 46) is a potent CXCR4 antagonist with an IC50 value of 79 nM. CXCR4 antagonist 6 inhibits CXCL12 induced cytosolic calcium flux (IC50 = 0.25 nM). CXCR4 antagonist 6 significantly mitigates CXCL12/CXCR4 mediated cell migration. CXCR4 antagonist 6 exhibits marked efficacy in a cancer metastasis model in mice .
    CXCR4 antagonist 6
  • HY-15568
    A-317491
    4 Publications Verification

    		 P2X Receptor Neurological Disease Inflammation/Immunology
    A-317491 is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux .
    A-317491
  • HY-15568A
    A-317491 sodium salt hydrate
    4 Publications Verification

    		 P2X Receptor Neurological Disease Inflammation/Immunology
    A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux .
    A-317491 sodium salt hydrate
  • HY-15297
    Vesnarinone
    1 Publications Verification

    OPC-8212

    		 Phosphodiesterase (PDE) Infection Cardiovascular Disease
    Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research .
    Vesnarinone
  • HY-124759
    CCR1 antagonist 9

    		CCR Inflammation/Immunology
    CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC50 of 6.8 nM in calcium flux assay .
    CCR1 antagonist 9
  • HY-116082
    CP 226269

    		Dopamine Receptor Neurological Disease
    CP 226269 is a potent dopamine D4 receptor agonist that induces calcium flux with EC50 of 32.0 nM. CP 226269 can be used in the research of schizophrenia and other related diseases .
    CP 226269
  • HY-16039
    AM095
    Maximum Cited Publications
    9 Publications Verification

    		 LPL Receptor Inflammation/Immunology
    AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
    AM095
  • HY-P3041
    Chromostatin (bovine)

    		Calcium Channel Endocrinology
    Chromostatin bovine is a chromogranin A (CGA) derivative peptide, which inhibits postassium or carbamoylcholine induced catecholamine release with an ID50 of 5 nM. Chromostatin bovine reduces calcium flux, enhances the desensitization process of the cholinergic-evoked secretory response and modulates the endocrine response associated with catecholamine .
    Chromostatin (bovine)
  • HY-101908
    BMS CCR2 22

    		CCR Inflammation/Immunology Endocrinology
    BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM) .
    BMS CCR2 22
  • HY-131349
    CCR4-351

    		CCR Cancer
    CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .
    CCR4-351
  • HY-131349A
    CCR4-351 hydrochloride

    		CCR Metabolic Disease Cancer
    CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .
    CCR4-351 hydrochloride
  • HY-143312D
    (R)-V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    (R)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R .
    (R)-V-0219 hydrochloride
  • HY-129555
    Surfactin
    5 Publications Verification

    		 Bacterial HSV Antibiotic Infection
    Surfactin is a potent cyclic lipopeptide biosurfactants consists of four isomers (Surfactin A, B, C and D), which mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes. Surfactin can act as an antimicrobial adjuvant with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects . Surfactin also has antiviral activity against a variety of enveloped viruses .
    Surfactin
  • HY-143312B
    (R)-V-0219

    		GLP Receptor Metabolic Disease
    (R)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R .
    (R)-V-0219
  • HY-P10408
    Candidalysin

    		EGFR MMP Calcium Channel Infection Inflammation/Immunology
    Candidalysin is a cytolytic peptide toxin, which is initially isolated from Candida albicans and exhibits virulent and avirulent characters. Candidalysin activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) of host cells, activates matrix metalloproteinase (MMP) and calcium flux, resulting in inflammatory responses and recruitment of immune cells. Candidalysin exhibits cytotoxicity by dealing membran damage to host cells .
    Candidalysin
  • HY-P1682
    Balixafortide

    POL6326

    		 CXCR Arrestin Cancer
    Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .
    Balixafortide
  • HY-P1682A
    Balixafortide TFA
    1 Publications Verification

    POL6326 TFA

    		 CXCR Arrestin Cancer
    Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .
    Balixafortide TFA
  • HY-143312C
    (S)-V-0219

    		GLP Receptor Metabolic Disease
    (S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .
    (S)-V-0219
  • HY-143312E
    (S)-V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    (S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .
    (S)-V-0219 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: